Insulin is so expensive mainly because of limited competition, complex pricing middlemen, and decades of policy gaps that allowed list prices to rise far faster than inflation, especially in the United States. Even though insulin is 100 years old and many core patents have expired, market power and opaque negotiations keep many patients paying high out‑of‑pocket costs. Recent reforms and price‑cut announcements have helped some people, but access and affordability problems remain widespread as of the mid‑2020s.

Quick Scoop

  • Three companies dominate most of the global insulin market, which lets them keep prices high with limited competitive pressure in many countries.
  • Prices rose sharply as prescribers shifted from older, cheaper human insulins to newer insulin analogs and as manufacturers repeatedly increased list prices.
  • Middlemen and rebates (like pharmacy benefit managers and complex insurer contracts) make the real price non‑transparent and can reward higher list prices.
  • Weak generic/biosimilar competition and “patent thickets” make it hard for cheaper alternatives to gain market share.
  • Insurance design (high deductibles, coinsurance) shifts more of the cost directly onto patients, leading to rationing and worse health outcomes.

Market power and lack of competition

  • The “Big Three” manufacturers—Eli Lilly, Novo Nordisk, and Sanofi—control the vast majority of global insulin sales by value, often more than 90%. In many countries only one of these companies has a strong presence, which functions like a local monopoly and allows aggressive pricing.
  • Limited true biosimilar and generic competition means there is little downward pressure on prices, even though many original patents have expired. Companies can also use tactics like “product hopping,” moving patients to newer versions just as older patents expire, which keeps cheaper options from gaining traction.

Complex, opaque pricing system

  • Insulin moves through a multi‑step supply chain: manufacturers, wholesalers, pharmacy benefit managers (PBMs), pharmacies, and insurers all negotiate separate prices and rebates. At each step, contracts are often confidential, so neither patients nor clinicians see what insulin actually costs.
  • Manufacturers argue that they raise list prices because PBMs and large health plans demand larger rebates in exchange for favorable formulary placement. This “rebate game” can paradoxically make high list prices attractive to intermediaries, while uninsured or under‑insured patients pay those high list prices at the counter.

Shift to newer analog insulins

  • Over the past few decades, many health systems have moved from older animal and human insulins to insulin analogs, which can offer benefits such as more predictable action profiles. These analogs are substantially more expensive than older formulations.
  • Studies of U.S. spending show that rising insulin expenditures are driven largely by switching to these newer, high‑priced products plus repeated price increases on all versions, not just by more people having diabetes. Growing obesity and insulin resistance do increase average doses per person, but this is a smaller piece of the total spending growth.

Insurance design and patient burden

  • As high‑deductible health plans and cost‑sharing became more common, many people with diabetes now pay a large share of insulin costs until they meet their deductible. This exposes them directly to the inflated list prices instead of the lower, negotiated net prices.
  • High out‑of‑pocket costs lead some patients to ration insulin, skip doses, or delay refills, which is associated with more hospitalizations and preventable complications. Advocacy groups highlight stories of patients facing “life‑or‑death” trade‑offs between insulin and other basic needs.

Policy responses and latest news context

  • In the past few years, several large manufacturers have announced list price cuts or caps on some insulin products in response to public and political pressure. Some U.S. policies, such as federal and state caps on monthly insulin copays for certain insured groups, are beginning to limit what some patients pay at the pharmacy.
  • However, many insulins and many patients are not fully covered by these measures, and advocates stress that “why is insulin still so expensive?” remains a live question in 2023–2025 forum and policy discussions. Global access problems persist, especially in low‑ and middle‑income countries where health systems and household incomes cannot absorb high prices.

TL;DR: Insulin stays expensive because a few powerful companies control the market, the pricing system rewards high list prices, competition is limited, and insurance designs often push those inflated costs onto patients, even as some recent reforms begin to chip away at the problem.

Information gathered from public forums or data available on the internet and portrayed here.